Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of MK-0736 in T2DM and Hypertension
NCT00806585Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0736 in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (5 arms), sponsored by Merck & Co. Primary endpoints: Sitting Diastolic Blood Pressure at 12 weeks and Sitting Systolic Blood Pressure at 12 weeks. Started Dec 2008; status: terminated.
02
Drugs
MK-0736
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT00806585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806585.